초록 ▼

Methods and systems are provided for the transdermal administration of racemic phenylpropanolamine, i.e., a mixture of two or more of the four isomers of phenylpropanolamine, (+)-norephedrine, (-)-norephedrine, (+)-norpseudoephedrine, and (-)-norpseudoephedrine. Generally, the racemate will be a mix

Methods and systems are provided for the transdermal administration of racemic phenylpropanolamine, i.e., a mixture of two or more of the four isomers of phenylpropanolamine, (+)-norephedrine, (-)-norephedrine, (+)-norpseudoephedrine, and (-)-norpseudoephedrine. Generally, the racemate will be a mixture of (+)-norephedrine and (-)-norephedrine. The racemic drug is administered along with a permeation enhancer. The permeation enhancer is preferably a basic compound, and optimally is a hydroxide-releasing agent such as sodium hydroxide.

대표청구항 ▼

Methods and systems are provided for the transdermal administration of racemic phenylpropanolamine, i.e., a mixture of two or more of the four isomers of phenylpropanolamine, (+)-norephedrine, (-)-norephedrine, (+)-norpseudoephedrine, and (-)-norpseudoephedrine. Generally, the racemate will be a mix

Methods and systems are provided for the transdermal administration of racemic phenylpropanolamine, i.e., a mixture of two or more of the four isomers of phenylpropanolamine, (+)-norephedrine, (-)-norephedrine, (+)-norpseudoephedrine, and (-)-norpseudoephedrine. Generally, the racemate will be a mixture of (+)-norephedrine and (-)-norephedrine. The racemic drug is administered along with a permeation enhancer. The permeation enhancer is preferably a basic compound, and optimally is a hydroxide-releasing agent such as sodium hydroxide. rid-3-yl)-1,2,5-thiadiazol-4-yloxy]-1-dodecyl acetate hydrochloride. 4. The method of claim 1, wherein the compound is tetra(ethylene glycol)mono[3-(1-methyl-1,2,5,6-tetrahydropyrid-3-yl)-1,2,5-thiadiazol-4-yl]ether hydrochloride. 5. The method of claim 1, wherein the compound is tetra(ethylene glycol)ethyl[3-1-methyl-1,2,5,6-tetrahydropyrid-3-yl)-1,2,5-thiadiazol-4-yl]ether hydrochloride. 6. The method of claim 1, wherein the compound is tetra(ethylene glycol)[3-(1-methyl-1,2,5,6-tetrahydropyrid-3-yl)-1,2,5-thiadiazol-4-yl]ether acetate hydrochloride. 7. The method of claim 1, wherein the compound is tetra(ethylene glycol)(4-methoxy-1,2,5-thiadiazol-3-yl)[3-(1-methyl-1,2,5,6-tetrahydropyrid-3-yl)-1,2,5-thiadiazol-4-yl]ether hydrochloride. individuals at risk for colorectal cancer," Cancer Epidemiology, Biomarkers & Prevention, 7:989-992, 1998. Marks et al., "The effects of DFMO on polyamine metabolism in the inner ear," Hear. Res., 53(2):230-236, 1991. McWilliams et al., "Characterization of the ototoxicity of difluoromethylornithine and its enantiomers," Toxicological Sciense, 56:124-132, 2000. Meyskens et al., "Dose de-escalation chemoprevention trial of α-difluoromethylornithine in patients with colon polyp," J. Natl. Cancer Inst, 86(15):1122-1130, 1994. Meyskens Jr. and Gerner, "Development of difluoromethylornithine (DFMO) as a chemoprevention agent," Clinical Cancer Research, 5:945-951, 1999. Meyskens, Jr. and Gerner, "Development of difluoromethylornithine as a chemoprevention agent for the management of colon cancer," J. Cell. Bio., 22:126-131, 1995. Pasic et al., "α-Difluoromethylornithine ototoxicity: chemoprevention clinical trial results," Arch. Otolaryngol. Head Neck Surg., 123(12):1281-1286, 1997. Salzer et al., "Cochlear damage and increased threshold in α-difluoromethylornithine (DFMO) treated guinea pigs," Hear. Res., 46:101-112, 1990. Schweitzer et al., "Identification of polyamines in the cochlea of the rat and their potential role in hearing," Brain Research Bulletin, 16:215-218, 1986. Wagner et al., "Resolution of the enantiomers of various alpha-substituted ornithine and lysine analogs by high-performance liquid chromatography with chiral eluant and by gas chromatography on Chirasil-Val," Anal Biochem 164(1):102-116, 1987. Bey et al., "Inhibition of Basic Amino Acid Decarboxylases Involved in Polyamine Biosynthesis," In: Inhibition of polyamine metabolism: biological significance and basis for new therapies. Edited by Peter McCann et al. Orlando: Academic Press, 1987. Bitonti et al., "Catalytic Irreversible Inhibition of TrypanosomaBrucei BruceiOrnithine Decarboxylase by Substrate and Product Analogs and Their Effects on Murine Trypanosomiasis," Biochemical Pharmacology, 34(10):1773-1777, 1985. Haegele et al., "Kinetics of α-difluoromethylornithine: An irreversible inhibitor of ornithine decarboxylase," Clin. Pharmacol. Ther., 30(2):210-217, 1981. International Patent Application Ser. No. PCT/US97/18252 filed Oct. 3, 1997. McCann and Pegg, "Ornithine Decarboxylase as an Enzyme Target for Therapy," Pharma. Ther., 5